PhRMA's Narasimhan Asks Japan To Reform Pricing Policies
Phase I Waiver Plan 'Very Positive'
Pointing to what it says is decreased R&D in Japan in contrast to the global market, PhRMA has again urged the country to revise its drug pricing policies and support innovation, while cautiously welcoming new moves to waive a requirement for Phase I trials in the country.
